药械

订阅

MedSci主页 / 所有栏目 / 药械

阿斯利康的三联疗法PT010在中国获批用于COPD患者

2019-12-24 Allan MedSci原创

PT010三联疗法COPD患者
关注

阿斯利康今天宣布，PT010（布地奈德/格隆溴铵/福莫特罗富马酸酯）已在中国获准用于维持治疗慢性阻塞性肺病（COPD）。PT010采用了创新的加压定量吸入器（pMDI）。

阿斯利康今天宣布，PT010（布地奈德/格隆溴铵/福莫特罗富马酸酯）已在中国获准用于维持治疗慢性阻塞性肺病（COPD）。PT010采用了创新的加压定量吸入器（pMDI）。

该项批准是基于III期KRONOS试验的结果，与双联疗法Bevespi Aerosphere和PT009相比，PT010显著改善了一秒钟内的低谷强制呼气量（FEV1）。PT010的安全性和耐受性与已知特征一致。来自KRONOS试验的数据于2018年10月发表在《柳叶刀呼吸医学》之上。阿斯利康生物制药研发执行副总裁Mene Pangalos表示：“慢性阻塞性肺病在中国影响着近1亿人口，是发病率和死亡率的主要原因。通过这一批准，我们现在可以提供功能强大的新型三联疗法”。


原始出处：

http://www.firstwordpharma.com/node/1689491#axzz68z4pBXnX

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970363, encodeId=9aa319e03632c, content=<a href='/topic/show?id=8876148247c' target=_blank style='color:#2F92EE;'>#PT010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14824, encryptionId=8876148247c, topicName=PT010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jan 20 17:02:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488851, encodeId=e7e914888515c, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Thu Dec 26 07:02:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613719, encodeId=893b1613e19dd, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Dec 26 07:02:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
    2020-01-20 naiwu77

    #PT010#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1970363, encodeId=9aa319e03632c, content=<a href='/topic/show?id=8876148247c' target=_blank style='color:#2F92EE;'>#PT010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14824, encryptionId=8876148247c, topicName=PT010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jan 20 17:02:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488851, encodeId=e7e914888515c, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Thu Dec 26 07:02:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613719, encodeId=893b1613e19dd, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Dec 26 07:02:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
    2019-12-26 gous

    #COPD患者#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1970363, encodeId=9aa319e03632c, content=<a href='/topic/show?id=8876148247c' target=_blank style='color:#2F92EE;'>#PT010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14824, encryptionId=8876148247c, topicName=PT010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jan 20 17:02:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488851, encodeId=e7e914888515c, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Thu Dec 26 07:02:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613719, encodeId=893b1613e19dd, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Dec 26 07:02:00 CST 2019, time=2019-12-26, status=1, ipAttribution=)]
    2019-12-26 12498636m55(暂无昵称)

    #三联疗法#

    0